U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars

Pacific Research Institute
November 3, 2021

Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at Pacific Research Institute.

“Generating Drug Savings Through Competition” explores the potential savings to patients and taxpayers from two drugs that currently do not face competition from biosimilars – Humira, which is the top selling drug in the United States, and Enbrel.

 

Read the study. . .

Biden’s new plan isn’t any better for your health

Washington Examiner | Sally C. Pipes
November 1, 2021

One provision that has survived is a massive and wasteful expansion of Obamacare . In March, Congress made federal tax credits available to those shopping for coverage on the exchanges with incomes above 400% of the federal poverty level — about $106,000 for a family of four. Those tax credits cap what they’d have to spend on a benchmark health plan at 8.5% of income through 2022.

Read the article here. . .

U.S. Bureaucrats Are An Impediment To Pandemic Recovery

Forbes.com | Sally C. Pipes
November 8, 2021

The FDA has also refused to accept trial data from studies conducted in other countries. In one instance earlier this year, the agency denied a company’s application because some of its trials were completed in Europe. Other companies have withdrawn their applications because they “heard” their data wouldn’t be accepted, according to a new ProPublica report.

Read more. . .

Democrats Abandon US Patients to Rescue Drug-Pricing Reform

Newsmax | Sally C. Pipes
November 4, 2021

These shakedown tactics will almost certainly result in fewer new medicines coming to market. In an analysis of a similar proposal, University of Chicago economist Tomas Philipson forecast that negotiations would reduce research and development spending by as much as $2 trillion and result in up to 342 fewer drugs making it to market over the next 20 years.

Read more. . .